New “Test’ Can Likely Predict Cancer 

( In the United Kingdom, doctors are using a new blood test that may identify cancer up to a year before the appearance of tumors. 

Many lives might be spared if this single blood test could identify the existence of cancer at its earliest stage or even before it begins.  

At least 25 kinds of cancer, including breast, pancreatic, lung, and colorectal, were predicted to emerge in a study with 1,000 participants, with the sick and healthy individuals distributed equally. The test revealed a “predisposition” for specific malignancies in certain individuals in the cancer-free group. 

In 2021, an Indian company called Epigeneres Biotech created the “first pan-cancer blood test,” which is being touted as the “holy grail” of cancer diagnosis.  

Dr. Sherif Raouf, a specialist in gastro­intestinal cancer who will oversee the experiment at London’s St. Bartholomew’s Hospital, said this “may be a game-changer.” 

He also said that detecting cancer at its early stage is the “holy grail of cancer treatment.” 

Ashish Tripathi, CEO of Tzar Laboratories and chairman of Epigeneres Biotech, claimed they did not receive even “one false negative, not even one false positive.” 

Tripathi said he could tell you which cancer you have and where it is growing just from a blood test. 

At its initial stages, a tumor produced from 1 billion cancer cells measures barely one cubic centimeter, making it difficult to detect even with CT scans. The tumors may spread cancer by shedding malignant cells as they expand. 

According to Tripathi, all cells originate from stem cells, but cancer cells “know” to become malignant because they contain a genetic signal. Although other blood tests look for evidence of fully developed tumor cells, Tripathi’s approach stands out because it explicitly targets stem cells with that genetic marker for cancer. 

Tripathi’s blood test could be the most significant breakthrough for early cancer diagnosis, but it may also benefit patients who have already been diagnosed by letting physicians know which organ(s) the cancer cells would target.